Identification of prodomain determinants involved in ADAMTS-1 biosynthesis.
The metalloprotease ADAMTS-1 (a disintegrin and metalloprotease with thrombospondin type I motif), similarly to other members of the ADAMTS family, is initially synthesized as a zymogen, proADAMTS-1, that undergoes proteolytic processing at the prodomain/catalytic domain junction by serine proteinases of the furin-like family of proprotein convertases. The goals of this study were to identify residues of the prodomain that play an essential role in ADAMTS-1 processing and to determine the identity of the convertase required for zymogen processing. To gain insight into the putative roles of specific prodomain residues in ADAMTS-1 biosynthesis, we performed biosynthetic labeling experiments in transiently transfected human embryonic kidney 293 cells expressing wild-type and prodomain mutants of proADAMTS-1. Cells expressing wild-type ADAMTS-1 initially produced a 110-kDa zymogen form that was later converted to an 87-kDa form, which was also detected in the media. Although convertases such as PACE4 and PC6B processed proADAMTS-1, we found that furin was the most efficient enzyme at producing the mature ADAMTS-1 87-kDa moiety. Site-directed mutagenesis of the two putative furin recognition sequences found within the ADAMTS-1 prodomain (RRNR173 and RKKR235) revealed that Arg235 was the sole processing site. Use of the Golgi disturbing agent, Brefeldin A, and monensin suggests that the cleavage of proADAMTS-1 takes place in the Golgi apparatus prior to its secretion. Conserved residues within the prodomain of other ADAMTS members hinted that they might act as maturation determinants. Replacement with alanine of selected residues Cys106, Tyr108, Gly110, Cys125, and Cys181 and residues encompassing the 137-144 sequence significantly affected the biosynthetic profile of the enzyme. Our results suggest that conserved residues other than the furin cleavage site in the prodomain of ADAMTS-1 are involved in its biosynthesis.
Longpré
Jean-Michel
JM
Department of Pharmacology, Faculty of Medicine, Université de Sherbrooke, Sherbrooke, Québec J1H 5N4, Canada.
Leduc
Richard
R
D051722:ADAM Proteins; D000071097:ADAMTS1 Protein; D000595:Amino Acid Sequence; D001665:Binding Sites; D001692:Biological Transport / Q000187:drug effects; D015153:Blotting, Western; D020126:Brefeldin A / Q000494:pharmacology; D017124:Conserved Sequence; D019483:Disintegrins / Q000096:biosynthesis* / Q000737:chemistry* / Q000235:genetics; D004622:Embryo, Mammalian; D004789:Enzyme Activation; D045683:Furin / Q000378:metabolism; D006031:Glycosylation; D006801:Humans; D007163:Immunosorbent Techniques; D007668:Kidney; D008666:Metalloendopeptidases / Q000096:biosynthesis* / Q000737:chemistry* / Q000235:genetics; D008969:Molecular Sequence Data; D008985:Monensin / Q000494:pharmacology; D016297:Mutagenesis, Site-Directed; D043484:Proprotein Convertases / Q000378:metabolism; D011498:Protein Precursors / Q000096:biosynthesis* / Q000737:chemistry* / Q000235:genetics; D016415:Sequence Alignment; D013329:Structure-Activity Relationship; D014162:Transfection
D019483:Disintegrins; D011498:Protein Precursors; D020126:Brefeldin A; D008985:Monensin; D043484:Proprotein Convertases; D045683:Furin; D051722:ADAM Proteins; D000071097:ADAMTS1 Protein; C103859:ADAMTS1 protein, human; D008666:Metalloendopeptidases